Carly Newton: Closing the Gap in Sickle Cell Disease Readmissions
Carly Newton, Sr Manager of Apheresis Clinical Marketing at Terumo Blood and Cell Technologies, shared a post on LinkedIn:
“1 in 3 adults with sickle cell disease are back in the hospital within 30 days of discharge. For some young adults, it’s closer to 40%.
Behind every one of those readmissions is another crisis, more missed work or school, more strain on a family.
The data is consistent: transfusion therapy, especially automated red blood cell exchange (aRBCX), lowers that risk, even for the sickest patients. Yet fewer than 3% of SCD patients access RBCX each year, despite most having the access and prescriber support to get it.
This September, for National Sickle Cell Awareness Month, I’m breaking down why that gap exists and what closing it could mean for the people living this every day.
Read the full article on my Substack.”
Stay updated withΒ Hemostasis Today.
-
Sep 15, 2026, 17:28Rachel Margolis-Goodman: When Conventional Treatment Could Not, Research Found an Answer
-
Sep 15, 2026, 17:26Jared Rice: Understanding Extreme Platelet Counts in Preterm Infants
-
Sep 15, 2026, 17:25Gregg W. Stone: OCT-Guided PCI Reduces Stent Thrombosis in Patients With Diabetes
-
Sep 15, 2026, 15:29Abdul Muqtadir Abbasi: Recognizing Thalassemia Trait Is Essential for Every Physician
-
Sep 15, 2026, 15:17Shehab Mohamed: A New Regional Consensus on HLH Diagnosis and Management
-
Sep 15, 2026, 15:17Sheharyar Raza: Managing Randomness in Artificial Intelligence for Transfusion Medicine
-
Sep 15, 2026, 15:00Sarah Wachtman: Modeling AAV-Based Gene Therapy for Hemophilia A Using Pediatric Liver Organoids
-
Sep 15, 2026, 15:00Ashenafi Tazebew Amare: From Blood Donation to Innovation and Patient Access
-
Sep 15, 2026, 14:56Glanzmann Thrombasthenia Beyond Platelet Transfusion